What is Pfizer's paxlovid — remaining performance obligation?

Pfizer (PFE) reported paxlovid — remaining performance obligation of $948.00M in Q1 2026.

What does paxlovid — remaining performance obligation mean?

The total value of contracted revenue for this product that has not yet been earned or recognized.

Products & Services · Remaining performance obligation

Paxlovid — Remaining performance obligation

Analysis

StatementSegment

CategoryGrowth

SignalHigher is better

VolatilityModerate

First reportedQ1 2026

Last reportedQ1 2026

Rolls up toRemaining performance obligations related to customer contracts that are unsatisfied or partially unsatisfied

How to read this metric

An increase indicates a growing backlog of contracted future sales, while a decrease suggests that the company is fulfilling its obligations faster than it is signing new contracts or that demand is softening.

Detailed definition

This metric represents the total transaction price allocated to performance obligations that are unsatisfied or partiall...

Peer comparison

Comparable to backlog or deferred revenue metrics in other pharmaceutical or long-term contract-based industries, reflecting future revenue visibility.

Metric ID: pfe_segment_paxlovid_remaining_performance_obligation

Historical Data

1 periods

	Q1 '26
Value	$948.00M

Similar Metrics at Other Companies

AbbottABT View metric

Arista NetworksANET View metric

Bloom EnergyBE View metric

BlackrockBLK View metric

General ElectricGE View metric

Motorola Solutions, Inc.MSI View metric

Frequently Asked Questions

What is Pfizer's paxlovid — remaining performance obligation?: Pfizer (PFE) reported paxlovid — remaining performance obligation of $948.00M in Q1 2026.
What does paxlovid — remaining performance obligation mean?: The total value of contracted revenue for this product that has not yet been earned or recognized.